Mini Oral News Today

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49...

17.10.2023 - FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) - Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and ... Seite 1

Data include three late-breaking abstracts, underscoring Astellas efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO, Oct. 15, 2023 /PRNewswire/ --...

Abstract highlights how NOX-A12 and radiotherapy remodel the immune tumor microenvironment in brain cancer patientsBERLIN--(BUSINESS WIRE)--Regulatory News:TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor micr...

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur...

FOSTER CITY, Calif., Oct. 16, 2023 -- Apollomics Inc. , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and...

Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), tod...

TME PHARMA ANNOUNCES SELECTION OF TWO CLINICAL ABSTRACTS ON THE ONGOING NOX-A12 GLORIA PHASE 1/2 TRIAL IN GLIOBLASTOMA FOR PRESENTATION AT...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...